Abstract
Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have